The United States now has 9 FDA-approved biosimilars. Our latest infographic breaks down what you need to know about these products.
The United States now has 9 FDA-approved biosimilars. Our latest infographic breaks down what you need to know about these products.
The Increasing Access to Biosimilars Act of 2023 Introduced to Congress
March 29th 2023The Increasing Access to Biosimilars Act of 2023 (HR 1352), a bill that would direct HHS to establish a demonstration project within Medicare that would establish a shared savings model for biosimilars, was introduced to the House of Representatives.
On the Come Up: What Vizient’s Report Says About Inflation and Biosimilars
February 26th 2023On this episode of Not So Different, Vizient’s Carina Dolan, PharmD, MS, BCOP, expounds on some of the results from Vizient’s recent edition of its Pharmacy Market Outlook Report, including how inflation could influence biosimilar utilization.
Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns
March 21st 2023At the Festival of Biologics, Juliana (Julie) Reed, executive director of the Biosimilars Forum, warned that without changes to encourage biosimilar uptake, companies will begin to ask the big question: Are biosimilars worth investing in?
2 Clarke Drive
Cranbury, NJ 08512